Videos

The search for immune system biomarkers that could prove clinically useful in treating patients with breast cancer is yielding promising results, particularly in triple-negative subtypes.

ASCO released new evidence-based recommendations to ensure appropriate use of biomarker assay results in guiding decisions on adjuvant therapy for women with early-stage invasive breast cancer and known estrogen receptor, progesterone receptor, and HER2 status.

Sacituzumab govitecan (IMMU-132) has received an FDA breakthrough therapy designation for the treatment of patients with triple-negative breast cancer following at least 2 treatments for metastatic disease.

Ingrid A. Mayer, MD, co-leader and Clinical Director, Breast Cancer Research Program Chair, Data and Safety Monitoring Committee, Associate Professor of Medicine (Hematology/Oncology), medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the use of targeted therapies in estrogen-receptor (ER)-positive breast cancer.

Patrick I. Borgen, MD, explains his strong opposition to the USPSTF guidelines and view that annual mammograms must remain a standard in clinical practice.

New strategies to increase the uptake of these proven breast cancer risk-reduction interventions in general clinical practice are needed.

The identification of the BRCA1 and BRCA2 tumor suppressor genes and the recognition that inherited loss of function (deleterious) mutations in one of these important genes places women at high risk for the development of breast, ovarian, and other cancers are major advances in women’s health research.

Aditya Bardia, MD, MPH, assistant professor of Medicine, Harvard Medical School, attending physician, Medical Oncology, Massachusetts General Hospital, discusses RAD1901, a selective estrogen receptor degrader (SERD) for potential use in ER-positive metastatic breast cancer.

One-third of patients previously identified as having HER2-positive breast cancer were found to also have a luminal subtype that was resistant to chemotherapy and trastuzumab but still sensitive to the triplet neoadjuvant regimen of pertuzumab, trastuzumab, and chemotherapy.

Peter Beitsch, MD, President at The American Society of Breast Surgeons, Dallas Surgical Group, discusses the impact of pertuzumab on patients with luminal subtype breast cancer.

The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations.

Oana C. Danciu, MD, assistant professor of Medicine, Division of Hematology/Oncology, University of Illinois Hospital and Health Sciences System, discusses a study examining a team-based approach to prescreen and identify breast cancer survivors using a survivorship care plan.

Tailoring your approach to how you interact with a patient can be beneficial.

Anees B. Chagpar, MD, shares her thoughts on the final US Preventive Services Task Force guidelines and how they change the focus of breast cancer screening.

Toshiaki Iwase, MD, Department of General Surgery, Chiba Graduate School of Medicine, Chiba, Japan, discusses a study that examined elevated neutrophil to lymphocyte ratio to predict survival outcomes after recurrence in patients with triple-negative breast cancer.